Global Hypertension Drugs Market 2014-2018


Naperville, IL -- (SBWIRE) -- 04/15/2014 -- Reportstack, provider of premium market research reports announces the addition of Global Hypertension Drugs Market 2014-2018 market report to its offering
About Hypertension Drugs
Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such as diet, exercising, and smoking are the major causes of hypertension. Hypertension can damage organs and lead to several illnesses such as renal failure, aneurysm, heart failure, stroke, and heart attack. There are two types of hypertension: primary or essential and secondary.
Analysts forecast the Global Hypertension Drugs market will grow at a CAGR of 1.2 percent over the period 2013-2018.
Covered in this Report
The Global Hypertension Drugs market can be categorized into eight segments: Diuretics, ACE Inhibitors, ARBs, CCB, Beta Blockers, Alpha Blockers, Vasodilators, and Renin Inhibitors. To calculate the market size, the report considers the revenue generated from the sales of various hypertension drugs used in the treatment of pulmonary arterial hypertension and essential hypertension.
Global Hypertension Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Hypertension Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
Key Vendors
Actelion Ltd.
AstraZeneca plc
Boehringer Ingelheim GmbH
Novartis AG
Pfizer Inc.
Sanofi SA
Other Prominent Vendors

Bayer AG
Daiichi Sankyo Co. Ltd.
Forest Laboratories Inc.
Merck & Co. Inc.
Takeda Pharmaceutical Co. Ltd.
United Therapeutics Corp.
Valeant Pharmaceuticals International Inc.
Key Market Driver
Increase in Aging Population.
For a full, detailed list, view our report.
Key Market Challenge
Increasing Number of Patent Expirations.
For a full, detailed list, view our report.
Key Market Trend
Increasing Focus on Combination Therapies.
For a full, detailed list, view our report.
Key Questions Answered in this Report
What will the market size be in 2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.

Companies Mentioned

Actelion Ltd., AstraZeneca plc , Boehringer Ingelheim GmbH , Novartis AG , Pfizer Inc., Sanofi SA, Bayer AG , Daiichi SankyoCo. Ltd., Forest Laboratories Inc., Merck & Co. Inc., Takeda Pharmaceutical Co. Ltd., United Therapeutics Corp., Valeant Pharmaceuticals International Inc., XOMA LLC

To view the table of contents for this market research report please visit
Roger Campbell
United States
Ph: 888-789-6604